CVC Credit, the €41 billion global credit management business of CVC, is pleased to announce that it has provided debt facilities to support the joint acquisition of Immedica Pharma (“Immedica”), a leading Swedish pharmaceutical company, by global investment firm KKR and Nordic healthcare investment firm Impilo.
Headquartered in Stockholm, Immedica launches and commercialises drugs for rare and specialty diseases, predominantly within genetic and metabolic diseases, haematology, oncology and specialty care. Immedica’s capabilities cover marketing and sales, compliance, pharmacovigilance, quality assurance, regulatory, medical affairs and market access, as well as a global distribution network serving patients in more than 50 countries across Europe, the Middle East and North Africa.
Moris Nachmias, Managing Director at CVC Credit, said: “Immedica has an impressive track record of profitable growth and strong financial performance since its founding in 2018. We look forward to supporting their continued expansion in the years ahead.”
Being part of the CVC Network has meant our team have been able leverage the knowledge of our Private Equity Healthcare team to help deliver this investment opportunity.
Simone ZacchiPartner at CVC Credit
Simone Zacchi, Partner at CVC Credit, added: “Being part of the CVC Network has meant our team have been able leverage the knowledge of our Private Equity Healthcare team to help deliver this investment opportunity. We are also pleased to be partnering with KKR again, having supported several of their recent acquisitions including APRIL Group.”
